Related Experiment Video
Updated: Nov 2, 2025
06:15
Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
Published on: August 9, 2024
1.5K
Extra-anogenital giant cutaneous squamous cell carcinomas require multidisciplinary management
Valerie van Dam1, Xuan Bich Trinh2, Bervoets An3
1Department of Internal Medicine, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.
Cancer Treatment and Research Communications
|June 14, 2021
Summary
Giant cutaneous squamous cell carcinoma (cSCC) is rare but can be aggressive. This review highlights a case on the breast and analyzes 42 extra-anogenital giant cSCC cases, emphasizing a multidisciplinary approach for optimal patient outcomes.
Area of Science:
- Dermatology
- Oncology
- Surgical Pathology
Background:
- Cutaneous squamous cell carcinoma (cSCC) is a common skin cancer with generally good prognosis.
- A subset of cSCC can progress to advanced or aggressive forms.
- Giant cSCC, defined by large tumor size, presents unique clinical challenges.
Observation:
- This study reports the first case of a giant cSCC on the breast.
- A systematic literature review identified 42 cases of extra-anogenital giant (EAG) cSCC.
- Patients were predominantly male (57%), with a median age of 70 years, and a median treatment delay of 12 months.
Findings:
- The most common locations for EAG cSCC were the head and neck (64%).
- Tumor stages were frequently advanced (T2-T4: 90%).
- Metastases were rare (2% lymph node, 2% distant), and radical surgical excision was the primary treatment (81%).
Implications:
- Giant cSCC, particularly EAG cSCC, poses significant treatment challenges.
- A multidisciplinary approach is crucial for managing these rare and potentially aggressive skin cancers.
- Early detection and intervention are vital for improving outcomes in advanced cSCC cases.
